Df-Life : Quality of Life in Patients With Fibrous Dysplasia

Fibrous Dysplasia Clinical Trial

— Df-Life  

Official title:

Df-Life : Quality of Life in Patients With Fibrous Dysplasia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05406544
• Other study ID #: 69HCL22_0374
• Secondary ID: 2022-A01239-34
• Status: Completed
• Start date: November 28, 2022
• Est. completion date: May 2, 2023

Study information

• Verified date: March 2024
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fibrous dysplasia (FD) is a congenital skeletal disorder with multiple complications such as bone pain, fractures, deformities and nerve compression. Few quantitative studies have demonstrated its physical, mental and social negative impacts on patients but none have qualitatively evaluated their global quality of life. Our hypothesis is that a better knowledge of the quality of life of FD patients should allow to target the actions to be implemented to improve patients'care.

The main objective of this qualitative research is therefore to investigate the quality of life of FD patients through 2 approaches: a qualitative study with focus groups interviews addressing several themes: self-image, psychological and emotional well-being, difficulties and adaptative strategies; and a quantitative study to measure the impact of FD on quality of life and on olfaction (sometimes affected by nerve compression due to the disease) using standardized questionnaires Short Form 36 (SF36) and Self-reported Mini Olfactory Questionnaire (SELF-MOQ).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 149
• Est. completion date: May 2, 2023
• Est. primary completion date: November 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women

• 18 years and more

• with Fibrous dysplasia

• Being followed in the rheumatology Department of the E. Herriot Hospital in Lyon.

• Non-opposition to take part in the study

• written consent to the audio recording of the discussions.

Exclusion Criteria:

• Legal incapacity or limited legal capacity

• Psychiatric or neurological condition that severely impairs comprehension

• Difficulty understanding spoken French

• Patients with another pathology with a major impact on quality of life

Related Conditions & MeSH terms

• Fibrous Dysplasia
• Fibrous Dysplasia of Bone
• Hyperplasia

Intervention

Other:
• FD qualitative study on quality of life
Patients will be contacted and focus groups will be organized with 6 to 8 patients presenting different types of FD: monostotic, polyostotic, with or without craniofacial damage. Several focus-groups will be conducted with men only or women only. Patients will be led in a semi-directive manner by a moderator who will use an interview grid listing all the topics to be addressed: symptoms, self-image, psychological and emotional well-being, difficulties in daily life and adaptative strategies. The discussions will be recorded and transcribed verbatim. Data will be analyzed manually by 2 investigators and with the help of a semantic analysis software. The objective is to bring out common notions about the quality of life of patients, their psychological and emotional well-being, their difficulties in daily life and their coping strategies according to their condition. Differences or similarities between men and women will be investigated.
• FD quantitative sudy on quality of life and olfaction.
Participants will receive 3 questionnaires to complete: the SF36 questionnaire (quality of life), the SELF-MOQ questionnaire (olfaction evaluation) and a demographic questionnaire. Other data required for the study will be extracted from the medical record: age, weight, height, affected bone sites, Radiological/ biological activity data, sensorial deficit, medication. For each questionnaire, scores will be calculated and compared between the different FD patient populations according to sex, age and type of FD.

Locations

Country	Name	City	State
France	Edouard Herriot Hospital - rheumatology	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FD Qualitative study: notions on quality of life	quality of life concepts that will emerge during group interviews.	during group interview (90 minutes)
Primary	FD Quantitative study: scores of quality of life and olfaction impairment	quality of life measured with SF36 score. Patients will answer to 11 questions. Olfaction impairment measured with SELF-MOQ olfaction score. Patients will answer to 14 questions	during 30 minutes